4

$VRTX · Vertex Pharmaceuticals Incorporated

November 18, 2026 · AI-analyzed SEC filing · Verify material figures against the official SEC.gov filing

This SEC Form 4 filing reports a change in beneficial ownership by Sangeeta N. Bhatia, a director of Vertex Pharmaceuticals Incorporated. According to the filing, Dr. Bhatia sold 271 shares of Vertex common stock on November 16, 2026, at a price of $547.86 per share. After the transaction, she directly held 4,653 shares of common stock.

The filing indicates that the sale was made pursuant to a company-approved trading plan under Rule 10b5-1, which Dr. Bhatia entered into on August 13, 2026. The form was signed on November 18, 2026, by an attorney-in-fact on her behalf.

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →